Previous close | 10,294.00 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 2,951,774 |
Market cap | 161.19B |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | 34.41 |
EPS (TTM) | 2.99 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 2.28 (2.21%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | 122.07 |
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
High drug prices in the United States have been the subject of growing political scrutiny for years. Senator Bernie Sanders and other lawmakers in January criticized the top four manufacturers of inhalers sold in the U.S. — AstraZeneca, Boehringer, Teva Pharmaceuticals and GSK — over high prices.
WILMINGTON, Del., March 18, 2024--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease (COPD), including those who are uninsured and underinsured.